Amneal Pharmaceuticals Quarterly Income Statement
NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amneal Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Amneal Pharmaceuticals generated $796.2 million in revenue, up 9.9% from the same quarter a year earlier. Net income was $57.7 million (+157.2% year over year), for a net margin of 7.2% versus a median of 3.1% in the prior 5 quarters. Gross margin was 42.0% (up from 39.5%) and operating margin 16.3%.
Diluted earnings per share came in at $0.18, up from $0.07.
Summary generated from market data by MetaCap's automated system. Methodology
Amneal Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 796.20M | 722.52M | 814.32M | 784.51M | 724.51M | 695.42M | 730.52M | 702.47M | 701.78M | 659.19M | 616.98M | 620.04M |
| Revenue growth (YoY) | +9.89% | +3.90% | +11.47% | +11.68% | +3.24% | +5.50% | +18.40% | +13.29% | +17.15% | +18.23% | +1.18% | +13.65% |
| Cost of Revenue | 461.69M | 402.41M | 517.13M | 510.54M | 438.25M | 439.53M | 467.64M | 432.91M | 451.83M | 421.13M | 427.15M | 387.51M |
| Gross Profit | 334.51M | 320.11M | 297.19M | 273.97M | 286.25M | 255.89M | 262.87M | 269.56M | 249.95M | 238.06M | 189.83M | 232.53M |
| Operating Expenses | 204.74M | 178.34M | 185.16M | 203.63M | 174.88M | 155.54M | 187.08M | 180.75M | 154.48M | 248.81M | 175.63M | 156.88M |
| Research & Development | 39.02M | 38.38M | 34.82M | 63.35M | 47.96M | 40.04M | 54.27M | 61.10M | 36.05M | 39.30M | 46.09M | 41.38M |
| Selling, General & Admin | 148.72M | 138.86M | 146.46M | 137.81M | 124.27M | 118.29M | 128.69M | 118.69M | 116.46M | 112.59M | 109.00M | 113.01M |
| Operating Income | 129.77M | 141.77M | 112.03M | 70.34M | 111.37M | 100.35M | 75.79M | 88.81M | 95.47M | -10.75M | 14.19M | 75.65M |
| Other Income (Expense) | -58.78M | -61.60M | -56.80M | -75.57M | -59.66M | -62.86M | -91.11M | -73.39M | -75.06M | -64.78M | -97.65M | -52.69M |
| Pretax Income | 70.99M | 80.18M | 55.23M | -5.22M | 51.71M | 37.49M | -15.32M | 15.42M | 20.41M | -75.52M | -83.46M | 22.96M |
| Income Tax | 1.38M | 2.18M | 5.66M | -23.36M | 16.10M | 12.87M | 5.42M | 3.67M | 3.62M | 6.16M | 9.88M | -2.08M |
| Net Income | 57.66M | 62.26M | 35.08M | 2.37M | 22.42M | 12.20M | -31.08M | -156.00K | 5.99M | -91.64M | -98.65M | 9.68M |
| Net Income growth (YoY) | +157.22% | +410.50% | — | — | +273.99% | — | — | -101.61% | -49.70% | — | — | — |
| EPS (Basic) | 0.18 | 0.20 | 0.11 | 0.01 | 0.07 | 0.04 | -0.10 | 0.00 | 0.02 | -0.30 | -0.57 | 0.06 |
| EPS (Diluted) | 0.18 | 0.19 | 0.10 | 0.01 | 0.07 | 0.04 | -0.10 | 0.00 | 0.02 | -0.30 | -0.57 | 0.06 |
| Shares Outstanding (Basic) | 319.20M | 316.02M | — | 314.17M | 313.74M | 311.05M | — | 309.65M | 309.12M | 307.28M | — | 154.22M |
| Shares Outstanding (Diluted) | 328.10M | 328.93M | — | 324.75M | 322.36M | 323.96M | — | 309.65M | 318.96M | 307.28M | — | 159.69M |
| Gross Margin | 42.01% | 44.31% | 36.50% | 34.92% | 39.51% | 36.80% | 35.98% | 38.37% | 35.62% | 36.11% | 30.77% | 37.50% |
| Operating Margin | 16.30% | 19.62% | 13.76% | 8.97% | 15.37% | 14.43% | 10.38% | 12.64% | 13.60% | -1.63% | 2.30% | 12.20% |
| Net Margin | 7.24% | 8.62% | 4.31% | 30.00% | 3.09% | 1.75% | -4.25% | -2.00% | 85.00% | -13.90% | -15.99% | 1.56% |
This table shows 12 quarterly periods of Amneal Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AMRX's reporting calendar. What is a income statement?